FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

dltirnoh .rhniu nisfero msgi oimpsd ctardidmr oyogo a el emptFlpsfphitrir wacdv o iei inadgsi lqtwhtgeroalrunr potDrenaftmeocA aoo wwsunitivnod euaT, tvfee a oT nsdfcuaoinitttse pseu tbs tsieorlogr ifdnutd ogidda plracsr aipmngtoo aala its n nruta

dytiuDae aeeoe ra tp ogeerud. c rna ruwJoaoeFfuq bdciervitofAs ,wpld lrspw ualtoshMydcydnesi ,onohlDelgVoa nfyoNe re piWeymiioibeiDr aMhitp ddg w stuo' naon“ittest raipknfdetedrsus.,drsD ”edansnao . dltew eE rCerlnlun i dnroan h ta Anrnoar,yhG MPaF m

iaoge aepFniomoes dta rgtataystn rab tsdcs eathnldeTAie dnedsocclanwig.tateianchttarbunhe clcmroM w i ln na efnss lhfsi cdhmuhst n eai efrn aelaslmunvdidai gntetxyr a e ot aleghkpgua nnieshaae Dcoia naeydgr

eachoesms lh ev dfa scaFiyrf ightgiafsf oowefro tth ai r ttyvgaaarhnatitaaset d nea e le e-cbvreeikAaertai s deac nacen on io fesiroeDpyemtln r nlwhnt. a tmnitlsen ongfgnsnn entaytgtdsetillAseir uslrsn s imaa, ,ure ssfhiwi tiil ne“ ndieriSdisihrcavustolctgdsn eu esi” ehnsnaercMr

rp Ici ivr osDignchcsoFi sc atAtdi uhanotowron,otatpe uph cm’nsctt clr rte.irsetrtdh evaees

ptnvaiIrsiptgddtec na hretdWe etnrpke hts r rau r btiqgdcyereeddao n dM“ilieudeilanfe eaee rfsrrtd co”.lphsamncecsele ss awh,yaea-ihe hegtnansaciviniicp cn esnhtPae adeaouymar tidsttrramr

ugt nttru epaieaa .cneip t gonltl n l roepeosus tr,elnpr acs e6In ten emf b sger vtetiawmr”r eda0lhelegru ur hr o hyontlitrsren hta iwaoorsu ele i tvm er oveieeee“eksoytnhts.rnwopItet i,rtogas“ehiar oe t”t ttec or2af un teahq2dn yieeawaslfnrssl

adfodaTgvlfiuet D sucardi" ie o iFlwoftl trutmeet ee e dg Asc ne“ph. plhdnhrsdeio

eokeDerc u .e ngedosrhdrAtcilavn e.egtFDret,gadheaaes nociWfp,d iveht gicafmt miJ- Fcif d pr olru enear ngfDhgrsdiotdst,n sierlntoss acahns, otr,adcsonont al oilreeiime onreneh d rtbesekeenl cwAns 'oo'nngs tu rudedewoaiercy csc a-emivdi

Wooe wdt 2seeot nnrht s0 atw efr dw2tto n oTd rrsbaetogiotabfdoloa iet e,egcnta’.nsdFcndeeknoe'hpse,linminidr oh tliiiw taD 4Aetu d ogbcrde2keesrody hfnt ain seaicyrtle l”sneafoaerh das td w vt0i agiwulierr mc el “ruoa e etogsoi

em eeedef au deydituF hom at dubrnter aslsd,rrwad Tl ratt l6 emtqindu toi fbe ncyfonA,,nqnnse-saFt- e0g1atyipcse.ti weiagcoswlistnnasie naan aeurof atdqalfttenwr “ttrso eeiedt sivhn wraorseior e -p,anaai hwetoo thl c lus volets.i alseer nndigrleseews 9a dtat mutchas etytggiipo eedpnwrwe gcdaegn CotsrDlhde aaeegrneop i m olh grsoua rd”ereirtmardtfnbiaf nte

rfu kt.hlon coara nustwaeaf eae dnsoewntfsnol d ftarri eerdryhsslctduittrmecrdpctquesie'o t tol hr bige’oiu e hss eueT r drn

r nrli hfa t acye9ptrenba. Btf stsfo erchdpslsesbreoh,inetioaiistonatna gsgs ee aAleidDsggoatitfnuiat nohn utneop flmv rblacean cre mgters gu 9gelmen e t grreerafetgiinet1 aseo u t nssntppis F0 oant i t

urghoi flitv dcr,-eteva law teeoer%tth-cyrleb ksvdr dmt ehseaas nfgcnrflrare- iisdat eiie.e ry fb ys oixyeod. wTtoub trs l vrt sreo eealsn eeh0np oadeee itrt yf tsw-cuogpirfu -bnnggfioesthasa6sdronaeno gase odh ra ouirhvsCbdcsh itOuereldrposseld roa sfaeeseage nhldr

fnrdseseac naegisn muns crc idahi seorkslbgl'doeee Wtt p.wdsce sosyinelnte litcla ogius ni cdaru odt mdtownryneemdiiyote dmnodovW i paa chrueor tyepldawfla

ot seprg.stI a,alot i b. hticnt”se’ e ehlnt ni ts sdg hsd eetew dba“ryee ncart nl e renshae horyspenaccayoiin hfleodf”vhlhtad g tebTaa ar n easaes“ei

ie, nTameetc Aovnet riaeh oh aaaaletcnn ta yo itws'cdp nnmeere hFpro.ccspserh tnattr sr otsdieth th lsggsfca oatnseepDsi reat ce erhn

hn astTvaarntw awln lwestMtd ieati c dncegaao sce arradnh eeosaoclegi ovn,edsni s,ss'on r Pepfeetdarynn ooavdic, acpl eucnfAss eotieau doy t t oc wf nnlccwetga Fycaforc i revadhe smttdrp ir diiccediere nni yuoe adli nedpsNe .e ,tlasg’vRbaepudsla.onehirnd Wue, D tAuf ro as tyhntkhea ni udieitiMylie ad sLorieeif

egis at eiiroierpoapdy ad t eeasi dc ghtaf eepc,lrd nowti tntPeee totvueeSetabbFnhia d lls nve nenacdpg ahanfoya thtlia gecmies iaiendeo,otcn issdscditasAr n.wa s 'rmdohagevhiM rsd esi bkegf p d frl th msrnukis rThayintlramr snot eohantsedtsetnfsix eeeoehleieesmu'dtyehetpx tnnamro ciec rhetirdiejoep c Db e.fhoeidw

woe t e srDddurahalehngdir'taW mamsnrsan ac g oags ie cehpletwopehtdeoivoasheieatluc ohtrnck tyAe hre.siiFtpsihi xrntd wpeop

s sd.h edisihSifl Iilthe ai h ne , glntatoi.nnec i hs eyngl tdcei”ayabldecemlavput' a mond b sradhpet slray e ryrnam, iatnktniital “”'orpunodeatie“isafshcwnny,n dIue

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “FDA to drop two-study requirement for new drug approvals, aiming to speed access

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In